Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

2021 ◽  
Vol 31 (4) ◽  
pp. 493-498
Author(s):  
Annamaria Offidani ◽  
Giulia Radi ◽  
Luca Bianchi ◽  
Serafinella Patrizia Cannavò ◽  
Andrea Conti ◽  
...  
Keyword(s):  
Systemic Treatment ◽  
Immunosuppressive Agents ◽  
Severe Psoriasis ◽  
Genital Infection

scholarly journals IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis

2022 ◽  
Vol 23 (1) ◽  
pp. 555
Author(s):  
Xing Wang ◽  
Hannah Kaiser ◽  
Amanda Kvist-Hansen ◽  
Benjamin D. McCauley ◽  
Lone Skov ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Plasma Proteins ◽  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Atherosclerotic Cardiovascular Disease ◽  
Strong Correlations ◽  
Potential Marker ◽  
Chronic Inflammatory Condition ◽  
Circulating Levels ◽  
Potential Biomarkers

Psoriasis is a chronic inflammatory condition associated with atherosclerotic cardiovascular disease (CVD). Systemic anti-psoriatic treatments mainly include methotrexate and biological therapies targeting TNF, IL-12/23 and IL-17A. We profiled plasma proteins from patients with moderate-to-severe psoriasis to explore potential biomarkers of effective systemic treatment and their relationship to CVD. We found that systemically well-treated patients (PASI < 3.0, n = 36) had lower circulating levels of IL-17 pathway proteins compared to untreated patients (PASI > 10, n = 23). Notably, IL-17C and PI3 were decreased with all four examined systemic treatment types. Furthermore, in patients without CVD, we observed strong correlations among IL-17C/PI3/PASI (r ≥ 0.82, p ≤ 1.5 × 10−12) pairs or between IL-17A/PASI (r = 0.72, p = 9.3 × 10−8). In patients with CVD, the IL-17A/PASI correlation was abolished (r = 0.2, p = 0.24) and the other correlations were decreased, e.g., IL-17C/PI3 (r = 0.61, p = 4.5 × 10−5). Patients with moderate-to-severe psoriasis and CVD had lower levels of IL-17A compared to those without CVD (normalized protein expression [NPX] 2.02 vs. 2.55, p = 0.013), and lower IL-17A levels (NPX < 2.3) were associated with higher incidence of CVD (OR = 24.5, p = 0.0028, 95% CI 2.1–1425.1). As a result, in patients with moderate-to-severe psoriasis, we propose circulating IL-17C and PI3 as potential biomarkers of effective systemic anti-psoriatic treatment, and IL-17A as potential marker of CVD.

Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study

2014 ◽  
Vol 24 (6) ◽  
pp. 662-669 ◽  
Author(s):  
Francisco Vanaclocha ◽  
Isabel Belinchón ◽  
José L. Sánchez-Carazo ◽  
Raquel Rivera ◽  
José M. Carrascosa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Cardiovascular Risk Factors ◽  
Systemic Treatment ◽  
Descriptive Study ◽  
Severe Psoriasis

scholarly journals Systemic treatment for severe psoriasis in a patient with autoimmune cytopenia

2020 ◽  
Vol 6 (3) ◽  
pp. 224
Author(s):  
Mary Kathryn Abel ◽  
Raagini Suresh ◽  
Jodie Raffi ◽  
Kristin Razzeca ◽  
Jenny E. Murase
Keyword(s):  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Autoimmune Cytopenia

Systemic Treatment of Severe Psoriasis

1991 ◽  
Vol 324 (5) ◽  
pp. 333-334 ◽  
Author(s):  
Nicholas J. Lowe
Keyword(s):  
Systemic Treatment ◽  
Severe Psoriasis

scholarly journals Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Seung Yong Choi ◽  
Jae Hoon Lee ◽  
Jae-Yon Won ◽  
Jeong Ah Shin ◽  
Young-Hoon Park
Keyword(s):  
Clinical Features ◽  
Systemic Treatment ◽  
Pulmonary Function Tests ◽  
Immunosuppressive Agents ◽  
Immunosuppressive Treatment ◽  
Pulmonary Sarcoidosis ◽  
Ocular Involvement ◽  
Treatment Rate ◽  
Ocular Manifestations ◽  
Systemic Treatments

Purpose. To investigate the clinical features and ocular manifestations of biopsy-proven pulmonary sarcoidosis in Korea. Methods. 55 patients diagnosed with pulmonary sarcoidosis by bronchoscopic or excisional biopsy were included. By retrospective clinical chart review, we investigated features of uveitis, ocular and systemic treatments, visual acuity, angiotensin-converting enzyme level, chest radiography, and pulmonary function tests. Clinical features were analyzed by presence of uveitis, site of biopsy, and first manifested sign of sarcoidosis. Results. The group with uveitis (n=39) presented with higher systemic (71.8%) and immunosuppressive treatment rates (35.9%) than the group without uveitis (31.3%, 0%, resp.) (P=0.007, P=0.005, resp.). There were no significant differences in clinical features, including systemic treatment rate, by type of biopsy. Of 39 patients with uveitis, the group with ocular manifestation as a first sign of sarcoidosis showed higher systemic and immunosuppressive treatment rates (88.9%, 55.6%) compared to the group with pulmonary manifestation as a first sign (57.1%, 19.0%) (P=0.037, P=0.018, resp.). Conclusions. In patients with biopsy-proven pulmonary sarcoidosis, the presence of ocular involvement and uveitis as a first sign could be significant factors associated with higher systemic treatment rate, especially with immunosuppressive agents. Biopsy site determined by location and size had no influence on clinical features.

scholarly journals Recommendations Russian Society of Dermatovenerologists and Cosmetologists for systemic treatment of psoriasis during the pandemic COVID-19

2020 ◽  
Vol 96 (2) ◽  
pp. 9-13
Author(s):  
Alexey A. Kubanov ◽  
Andrey L. Bakulev ◽  
Muza M. Kokhan ◽  
Olga Yu. Olisova ◽  
ALexey V. Samtsov ◽  
...  
Keyword(s):  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Published Data ◽  
Russian Society ◽  
Clinical Recommendations

Below you will find the analysis of the first published data and international clinical recommendations for the systemic treatment of patients with moderate and severe psoriasis in the context of the COVID-19 pandemic in different countries (France, Italy, USA, Spain, and Germany).

scholarly journals Systemic treatment of psoriasis: from methotrexate to biologics

2020 ◽  
Vol 96 (3) ◽  
pp. 7-26
Author(s):  
Olga Yu. Olisova ◽  
Ekaterina M. Anpilogova
Keyword(s):  
Skin Diseases ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Certolizumab Pegol ◽  
Severe Psoriasis ◽  
Unknown Etiology ◽  
Inflammatory Skin Diseases ◽  
New Era ◽  
Complete Clinical Remission

Psoriasis is one of the most frequent chronic inflammatory skin diseases and it has been of interest to many scientists for ages. The review presents data on all systemic treatment options, that are to date officially registered in Russian Federation for moderate-to-severe psoriasis. Aspects of the mechanism of action, efficacy and tolerability of both basic drugs (methotrexate, cyclosporine, acitretin) and biologics (infliximab, adalimumab, etanercept, certolizumab pegol, ustekinumab, guselkumab, secukinumab, ixekizumab, netakimab) and small molecules (tofacitinib, apremilast) are considered in detail. Special emphasis is placed on the important nuances of biological therapy: immunogenicity, drugs' survival and switch due to lack of efficacy. Invention of biologics signified a new era of moderate-to-severe psoriasis treatment. It became possible to achieve complete clinical remission more safely, which significantly improved the quality of life of patients. However, due to the unknown etiology of psoriasis, there is still no universal remedy that would allow to cure every patient, this fact makes scientists from all over the world keep conducting numerous clinical trials to find even more effective and safe therapeutic options.

Sign in / Sign up

Export Citation Format

Share Document